These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23288236)

  • 1. 5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial.
    Kato M; Nonen S; Serretti A; Tetsuo S; Takekita Y; Azuma J; Kinoshita T
    J Clin Psychopharmacol; 2013 Feb; 33(1):131-2. PubMed ID: 23288236
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.
    Kato M; Fukuda T; Wakeno M; Fukuda K; Okugawa G; Ikenaga Y; Yamashita M; Takekita Y; Nobuhara K; Azuma J; Kinoshita T
    Neuropsychobiology; 2006; 53(4):186-95. PubMed ID: 16874005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression.
    Morishita S; Arita S
    Hum Psychopharmacol; 2003 Aug; 18(6):479-82. PubMed ID: 12923828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs.
    Kato M; Serretti A; Nonen S; Takekita Y; Wakeno M; Azuma J; Kinoshita T
    Transl Psychiatry; 2015 Feb; 5(2):e513. PubMed ID: 25710119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights and barriers to clinical use of serotonin transporter pharmacogenetics in antidepressant therapy.
    Stevenson JM
    Pharmacogenomics; 2018 Feb; 19(3):167-170. PubMed ID: 29325499
    [No Abstract]   [Full Text] [Related]  

  • 6. [Possibility of a pharmacogenetic approach for prediction and personalized medication in major depressive disorder treatment].
    Kato M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):83-92. PubMed ID: 20491282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysfunctional attitudes and the serotonin transporter promoter polymorphism (5-HTTLPR).
    Whisman MA; Johnson DP; Smolen A
    Behav Ther; 2011 Jun; 42(2):300-5. PubMed ID: 21496514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lithium overcomes the influence of 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation.
    Benedetti F; Barbini B; Bernasconi A; Fulgosi MC; Campori E; Colombo C; Dallaspezia S; Lorenzi C; Pontiggia A; Radaelli D; Smeraldi E
    J Clin Psychopharmacol; 2008 Apr; 28(2):249-51. PubMed ID: 18344745
    [No Abstract]   [Full Text] [Related]  

  • 9. BDNF gene polymorphisms are associated with Alzheimer's disease-related depression and antidepressant response.
    Zhang L; Fang Y; Zeng Z; Lian Y; Wei J; Zhu H; Jia Y; Zhao X; Xu Y
    J Alzheimers Dis; 2011; 26(3):523-30. PubMed ID: 21677379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol and serotonin transporter polymorphism interactions in late-life depression.
    Kim JM; Stewart R; Kim SW; Shin IS; Yang SJ; Yoon JS
    Neurobiol Aging; 2011 Feb; 32(2):336-43. PubMed ID: 19329228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-HTTLPR modulates antidepressant efficacy in depressed women.
    Gressier F; Bouaziz E; Verstuyft C; Hardy P; Becquemont L; Corruble E
    Psychiatr Genet; 2009 Aug; 19(4):195-200. PubMed ID: 19451862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine.
    Reimherr F; Amsterdam J; Dunner D; Adler L; Zhang S; Williams D; Marchant B; Michelson D; Nierenberg A; Schatzberg A; Feldman P
    Psychiatry Res; 2010 Jan; 175(1-2):67-73. PubMed ID: 19969374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder.
    Kang RH; Wong ML; Choi MJ; Paik JW; Lee MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1317-21. PubMed ID: 17618721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between SERTPR and stressful life events on response to antidepressant treatment.
    Mandelli L; Marino E; Pirovano A; Calati R; Zanardi R; Colombo C; Serretti A
    Eur Neuropsychopharmacol; 2009 Jan; 19(1):64-7. PubMed ID: 18815011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients.
    Yoshida K; Ito K; Sato K; Takahashi H; Kamata M; Higuchi H; Shimizu T; Itoh K; Inoue K; Tezuka T; Suzuki T; Ohkubo T; Sugawara K; Otani K
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb; 26(2):383-6. PubMed ID: 11817517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics and the serotonin transporter in late-life depression.
    Gerretsen P; Pollock BG
    Expert Opin Drug Metab Toxicol; 2008 Dec; 4(12):1465-78. PubMed ID: 19040324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine.
    Inoue T; Honda M; Kawamura K; Tsuchiya K; Suzuki T; Ito K; Matsubara R; Shinohara K; Ishikane T; Sasaki K; Boku S; Fujisawa D; Ono Y; Koyama T
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):223-7. PubMed ID: 22504727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine.
    Yoshida K; Higuchi H; Kamata M; Takahashi H; Inoue K; Suzuki T; Itoh K; Ozaki N
    J Psychopharmacol; 2007 Aug; 21(6):650-6. PubMed ID: 17092970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic studies of drug response and side effects in the STAR*D study, part 2.
    Garriock HA; Hamilton SP
    J Clin Psychiatry; 2009 Sep; 70(9):1323-5. PubMed ID: 19818256
    [No Abstract]   [Full Text] [Related]  

  • 20. From pharmacogenetics to imaging pharmacogenetics: elucidating mechanisms of antidepressant response.
    Brandl EJ; Walter H
    Pharmacogenomics; 2017 Jul; 18(10):927-930. PubMed ID: 28639501
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.